Wednesday, January 15, 2025 7:03:14 PM
Is Vazkepa looked at as a valuable drug?
We now have ((8)) generics in the US market. Yes there is a big recognition of Vasecpa making a difference in CV care.
The Europeans are a little slow in understanding a statin patient being released from the hospital after a heart attack should see Vazkepa added to their therapy. Getting to a critical number of patients and doctors in Europe will put a lot of pressure on other doctors to get on top of what is the best care for these patients. That would be hundred of thousands of HA patients that should at teast be given the choice.
.
My Doc still thinks fish oil has some medicinal value. This year he finally brought up Vascepa to me as off label use as my blood lipids edged into the treatment zone. I've actually talked to him about Vascepa in the past and he was clueless and always acted uninterested. European medicine is apparently not incentivized to keep up to date and are also on the slow track with Vazkepa. I think once that snowball of Vazkepa users gets big enough there is real potential Vaskepe it will gain traction. My Doc was actually interested in me starting Vascepa off label, for me that was a huge statement.
We now have ((8)) generics in the US market. Yes there is a big recognition of Vasecpa making a difference in CV care.
The Europeans are a little slow in understanding a statin patient being released from the hospital after a heart attack should see Vazkepa added to their therapy. Getting to a critical number of patients and doctors in Europe will put a lot of pressure on other doctors to get on top of what is the best care for these patients. That would be hundred of thousands of HA patients that should at teast be given the choice.
.
My Doc still thinks fish oil has some medicinal value. This year he finally brought up Vascepa to me as off label use as my blood lipids edged into the treatment zone. I've actually talked to him about Vascepa in the past and he was clueless and always acted uninterested. European medicine is apparently not incentivized to keep up to date and are also on the slow track with Vazkepa. I think once that snowball of Vazkepa users gets big enough there is real potential Vaskepe it will gain traction. My Doc was actually interested in me starting Vascepa off label, for me that was a huge statement.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
